Diagnostics Industry

Found 2,498 articles

• Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis

  10/22/2019

  Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021

• HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29

  10/22/2019

  HTG Molecular Diagnostics, Inc. announced that it will host a Key Opinion Leader luncheon at 12:00 pm ET on Tuesday, October 29th in New York City.

• Veracyte Announces Third Quarter 2019 Financial Results and Business Progress

  10/22/2019

  Veracyte, Inc. announced financial results and business progress for the third quarter ended September 30, 2019.

• OrigiMed: The largest cohort study on HBV-Related hepatocellular carcinoma in China released in Cell

  10/22/2019

  The world-class journal Cell, an international high-impact journal, published the article "Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma in China."

• Dr. Mark H. Pollack named Chief Medical Officer for Myriad NeuroscienceHighly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice

  10/21/2019

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad Neuroscience effective Jan. 15, 2020.

• Quotient Limited to Report Second Quarter 2020 Financial Results and Host Conference Call

  10/21/2019

  Quotient Limited, a commercial-stage diagnostics company, announced that financial results for its fiscal second quarter ended September 30, 2019, will be released before market open on Monday, November 4, 2019.

• Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node

  10/18/2019

  Castle Biosciences, Inc. announced the presentation of data supporting the ability of the DecisionDx®-Melanoma gene expression profile test to identify T1 melanoma patients at low risk for a positive sentinel lymph node at the American Society of Dermatopathology 56th Annual Meeting in San Diego from October 17-20.

• Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

  10/18/2019

  VolitionRx Limited announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department will be presenting at the Veterinary Cancer Society Annual Conference in Houston taking place this weekend.

• Aalto Bio Reagents Launches World's First Commercially Available Venezuela Equine Encephalitis Virus (VEEV) Protein

  10/17/2019

  On the occasion of the first market partnership for Japan Aalto Bio Reagents launches the first commercially available protein for the detection and diagnosis of Venezuela Equine Encephalitis NSP2 TC83.

• Predictive Laboratories Team Led by Laboratory Director Kenneth Ward, M.D. Receives 2019 Endometriosis Special Interest Group Prize Paper AwardResearch presented by Dr. Hans Albertsen of Juneau Biosciences advancing knowledge

  10/17/2019

  Predictive Laboratories announces Kenneth Ward, M.D., laboratory director of Predictive Laboratories and chief executive officer of Juneau Biosciences; Rakesh Chettier M.S., director of biostatistics of Predictive Laboratories; and Hans Albertsen, Ph.D., chief scientific officer of Juneau Biosciences, have received the 2019 Endometriosis Special Interest Group Prize Paper in the “Best in Clinical/Population Science” category.

• DCN Dx and QIAGEN Lake Constance announce five finalists for Rapid Testing Innovation Award

  10/16/2019

  DCN Dx and Qiagen Lake Constance are pleased to announce five finalists for its second Rapid Testing Innovation Award.

• Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma

  10/16/2019

  Data presented at American Academy of Ophthalmology 2019 Annual Meeting

• Co-Diagnostics Expands Vector Control Marketing Nationwide

  10/15/2019

  Vector Smart™ products being presented at 6 vector control conferences in October to prepare for 2020 mosquito season

• New Data from Ambry Genetics Demonstrates Impact of First Major Advancement in Over 10 Years to Increase Diagnostic Yield in Genetic Testing for Hereditary Cancer Risk

  10/15/2019

  In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results.

• HTG Announces the Launch of its New Autoimmune Profiling Assay

  10/15/2019

  HTG Molecular Diagnostics, Inc. announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory at the end of October 2019.

• CADET® BRAF and BRAF-PLUS now available exclusively through Antech Diagnostics

  10/15/2019

  First liquid biopsy for the veterinary industry offers simple, non-invasive way to detect the most common canine bladder and prostate cancer

• Ortho Clinical Diagnostics Expands Drugs of Abuse and Therapeutic Drug Assay Menus in Collaboration With Thermo Fisher Scientific

  10/15/2019

  New MicroTip Partnership Assays (MPAs) Help Detect the Use of Fentanyl and Tricyclic Antidepressants (TCA)

• Excellere Portfolio Company, Biocare Medical, Appoints Nicolas Barthelemy as Executive Chairman

  10/14/2019

  Biocare Medical, a leading developer of world-class immunohistochemistry and molecular reagents and instrumentation, announced the appointment of Nicolas Barthelemy as Executive Chairman. Mr. Barthelemy brings over 25 years of executive leadership experience in the life sciences and diagnostic tools industry.

• Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®

  10/14/2019

  Data from Prospective, Observational Study will Strengthen Clinical Evidence and Support Continued Cologuard Adoption

• Predictive Laboratories Announces Commercialization & Full Market Availability Of ARTguide™ At American Society Of Reproductive Medicine (ASRM) Scientific Congress & ExpoCompany also presenting 2 oral & 1 poster scientific presentations at ASRM

  10/10/2019

  Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group focused on hard-to-detect diseases, women’s health and infertility, announces the commercialization and full market availability of ARTguide, the first integrated, DNA-based test that evaluates the risk for endometriosis and other genetic causes of infertility in women.